Cognitive effects of statin medications

Brendan J. Kelley, Stephen Glasser

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Administration issued updated recommendations regarding statin medications, and the panel's comments regarding memory impairment fostered clinical confusion (in part because of the lay media's amplification). Cognitive data from several large epidemiological studies have not reliably demonstrated a robust association between incident cognitive impairment and statin use, with some studies reporting a protective effect, some reporting an increased risk and others finding no association. Although several interventional studies have evaluated statins as a possible adjunctive treatment for Alzheimer's disease, none have clearly demonstrated a benefit. A small number of case series have reported infrequent memory difficulties associated with statin use. In these series, the patients' cognitive symptoms resolved after statin discontinuation. The existing medical literature does not suggest that cognitive considerations should play a major role in medical decision making to prescribe statins for the large majority of patients. As with any medication prescribed for older adults, careful clinical monitoring for side effects should be exercised. If a patient is suspected of having idiosyncratic memory impairment associated with use of a statin medication, the drug can be discontinued. The patient should then be followed with careful clinical observation for 1-3 months for resolution of the cognitive symptoms.

Original languageEnglish (US)
Pages (from-to)411-419
Number of pages9
JournalCNS Drugs
Volume28
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Neurobehavioral Manifestations
Cerebrovascular Disorders
Confusion
United States Food and Drug Administration
Epidemiologic Studies
Alzheimer Disease
Oxidoreductases
Cardiovascular Diseases
Observation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology
  • Medicine(all)

Cite this

Cognitive effects of statin medications. / Kelley, Brendan J.; Glasser, Stephen.

In: CNS Drugs, Vol. 28, No. 5, 01.01.2014, p. 411-419.

Research output: Contribution to journalArticle

Kelley, Brendan J. ; Glasser, Stephen. / Cognitive effects of statin medications. In: CNS Drugs. 2014 ; Vol. 28, No. 5. pp. 411-419.
@article{6578fd39ced74002aa0f0aa30ed48857,
title = "Cognitive effects of statin medications",
abstract = "The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Administration issued updated recommendations regarding statin medications, and the panel's comments regarding memory impairment fostered clinical confusion (in part because of the lay media's amplification). Cognitive data from several large epidemiological studies have not reliably demonstrated a robust association between incident cognitive impairment and statin use, with some studies reporting a protective effect, some reporting an increased risk and others finding no association. Although several interventional studies have evaluated statins as a possible adjunctive treatment for Alzheimer's disease, none have clearly demonstrated a benefit. A small number of case series have reported infrequent memory difficulties associated with statin use. In these series, the patients' cognitive symptoms resolved after statin discontinuation. The existing medical literature does not suggest that cognitive considerations should play a major role in medical decision making to prescribe statins for the large majority of patients. As with any medication prescribed for older adults, careful clinical monitoring for side effects should be exercised. If a patient is suspected of having idiosyncratic memory impairment associated with use of a statin medication, the drug can be discontinued. The patient should then be followed with careful clinical observation for 1-3 months for resolution of the cognitive symptoms.",
author = "Kelley, {Brendan J.} and Stephen Glasser",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s40263-014-0147-5",
language = "English (US)",
volume = "28",
pages = "411--419",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Cognitive effects of statin medications

AU - Kelley, Brendan J.

AU - Glasser, Stephen

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Administration issued updated recommendations regarding statin medications, and the panel's comments regarding memory impairment fostered clinical confusion (in part because of the lay media's amplification). Cognitive data from several large epidemiological studies have not reliably demonstrated a robust association between incident cognitive impairment and statin use, with some studies reporting a protective effect, some reporting an increased risk and others finding no association. Although several interventional studies have evaluated statins as a possible adjunctive treatment for Alzheimer's disease, none have clearly demonstrated a benefit. A small number of case series have reported infrequent memory difficulties associated with statin use. In these series, the patients' cognitive symptoms resolved after statin discontinuation. The existing medical literature does not suggest that cognitive considerations should play a major role in medical decision making to prescribe statins for the large majority of patients. As with any medication prescribed for older adults, careful clinical monitoring for side effects should be exercised. If a patient is suspected of having idiosyncratic memory impairment associated with use of a statin medication, the drug can be discontinued. The patient should then be followed with careful clinical observation for 1-3 months for resolution of the cognitive symptoms.

AB - The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Administration issued updated recommendations regarding statin medications, and the panel's comments regarding memory impairment fostered clinical confusion (in part because of the lay media's amplification). Cognitive data from several large epidemiological studies have not reliably demonstrated a robust association between incident cognitive impairment and statin use, with some studies reporting a protective effect, some reporting an increased risk and others finding no association. Although several interventional studies have evaluated statins as a possible adjunctive treatment for Alzheimer's disease, none have clearly demonstrated a benefit. A small number of case series have reported infrequent memory difficulties associated with statin use. In these series, the patients' cognitive symptoms resolved after statin discontinuation. The existing medical literature does not suggest that cognitive considerations should play a major role in medical decision making to prescribe statins for the large majority of patients. As with any medication prescribed for older adults, careful clinical monitoring for side effects should be exercised. If a patient is suspected of having idiosyncratic memory impairment associated with use of a statin medication, the drug can be discontinued. The patient should then be followed with careful clinical observation for 1-3 months for resolution of the cognitive symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84901501976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901501976&partnerID=8YFLogxK

U2 - 10.1007/s40263-014-0147-5

DO - 10.1007/s40263-014-0147-5

M3 - Article

C2 - 24504830

AN - SCOPUS:84901501976

VL - 28

SP - 411

EP - 419

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 5

ER -